Don’t split up the dynamic duo of GSK’s vaccines and drugs, vax chief says

Carly Helfand

Prominent U.K. investor Neil Woodford has been calling for a four-way breakup of GlaxoSmithKline, a company he is too "complicated" for its own good. But take it from GSK Moncef Slaoui–splitting apart is a bad idea, at least on the vaccines front.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS